Dr. Stephen W. Behrman
Claim this profileBaptist Memorial Hospital and Cancer Center-Memphis
Studies Pancreatic Cancer
Studies Cancer
7 reported clinical trials
20 drugs studied
Area of expertise
1Pancreatic Cancer
BRCA1 positive
BRCA2 positive
PALB2 positive
2Cancer
Stage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Stephen W. Behrman is currently running
Pre- and Post-Surgery Chemotherapy
for Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Recruiting1 award Phase 2 & 315 criteria
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
More about Stephen W. Behrman
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Stephen W. Behrman has experience with
- Cefoxitin
- Piperacillin-tazobactam
- Pre-Surgical Toolkit (OPTI-Surg)
- Endoscopic Ultrasound
- Computed Tomography
- Magnetic Resonance Imaging
Breakdown of trials Stephen W. Behrman has run
Pancreatic Cancer
Adenosquamous Carcinoma
Pancreatic Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen W. Behrman specialize in?
Stephen W. Behrman focuses on Pancreatic Cancer and Cancer. In particular, much of their work with Pancreatic Cancer has involved BRCA1 positive patients, or patients who are BRCA2 positive.
Is Stephen W. Behrman currently recruiting for clinical trials?
Yes, Stephen W. Behrman is currently recruiting for 5 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Stephen W. Behrman has studied deeply?
Yes, Stephen W. Behrman has studied treatments such as Cefoxitin, Piperacillin-tazobactam, Pre-Surgical Toolkit (OPTI-Surg).
What is the best way to schedule an appointment with Stephen W. Behrman?
Apply for one of the trials that Stephen W. Behrman is conducting.
What is the office address of Stephen W. Behrman?
The office of Stephen W. Behrman is located at: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee 38120 United States. This is the address for their practice at the Baptist Memorial Hospital and Cancer Center-Memphis.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.